Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

crop smart pty ltd - imazapyr present as isopropylamine salt - soluble concentrate - imazapyr present as isopropylamine salt imidazolinone active 250.0 g/l - herbicide - agricultural non-crop areas | agricultural/farm buildings | commercial/industrial premises | public service area | rights of way - annual ryegrass | barnyard grass or water grass | blackberry nightshade | blady grass | bokhara clover | bracken - suppression | capeweed | couch | deadnettle | dock | feathertop rhodes grass | fleabane | johnson grass | liverseed or urochloa grass | london rocket | mayne's pest | medic | melilotus or hexham scent | mintweed | panics - suppression | paspalum | paterson's curse | plains grass | prairie grass | prickly lettuce | purple top | queensland bluegrass | rubber vine | scented top | sedge | slender celery | soft roly poly | sowthistles | st barnaby's thistle | stinging or dwarf nettle | summer grass | thornapple | thunbergia | turnip weed | variegated thistle | vasey grass | warrego grass | wild oat | wild turnip | wireweed, knotweed or hogweed | annual dwarf nettle | annual medic | annual nettle | black nightshade | blessed thistle | blue salvia | blue thunbergia | blue top | blue trumpet vine | brassica campestris | brassica rapa ssp. sylvestris | brassica rapa var. sylvestris | bristly speargrass |

Australia - English - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - procaine benzylpenicillin, quantity: 1.5 g - injection, suspension - excipient ingredients: sodium citrate dihydrate; water for injections; polysorbate 80 - indications as at 18 february 2002: treatment of moderately severe infections due to penicillin sensitive organisms. therapy should be guided by bacteriological studies, including sensitivity tests and also by clinical response. infections which usually respond to adequate dosage are: group a streptococcal infections including upper respiratory tract infections, skin and skin structure infections and scarlet fever; pneumococcal infections of the respiratory tract; susceptible staphylococcal infections, most gonococcal infections, syphilis, fusospirochaetosis (vincent's gingivitis and pharyngitis). cilicaine syringe 1.5 must be administered by the intramuscular route only (see section 4.2 dose and method of administration).

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

bioproperties pty. ltd. - newcastle disease strain v-4 virus - misc. vaccines or anti sera - newcastle disease strain v-4 virus vaccine-viral active 0.0 eid 50/d - immunotherapy - poultry broilers (meat for human consum) | chickens | chooks | meat birds - newcastle disease

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

axichem pty ltd - pyriproxyfen; liquid hydrocarbon - emulsifiable concentrate - pyriproxyfen pyridine active 100.0 g/l; liquid hydrocarbon solvent other 450.0 g/l - insecticide

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

bayer cropscience pty ltd - pyrasulfotole; bromoxynil mixed heptanoic acid & octanoic acid esters; mefenpyr-diethyl; liquid hydrocarbon - emulsifiable concentrate - pyrasulfotole ungrouped active 37.5 g/l; bromoxynil mixed heptanoic acid & octanoic acid esters ester active 210.0 g/l; mefenpyr-diethyl pyrazoline other 9.4 g/l; liquid hydrocarbon solvent other 381.0 g/l - herbicide - barley - see label for exceptions | cereal rye - see label | triticale - see label | wheat - see label for exceptions | tritical - amsinckia, yellow burrweed - seedling | bedstraw | bifora, carrot weed or bird's eye | bindweed | capeweed | corn gromwell, ironweed or sheepweed | deadnettle | fumitory | indian hedge mustard | paterson's curse | prickly lettuce | saffron thistle | shepherd's purse | sowthistles | three cornered jack or doublegee | turnip weed | volunteer canola | volunteer chickpea | volunteer faba bean | volunteer field pea | volunteer lentil | volunteer lucerne - seedling | volunteer lupin | volunteer medic | volunteer vetch or tares | wild radish or radish weed | wild turnip | wireweed, knotweed or hogweed | amsinckia angustifolia | amsinckia calycina | amsinckia hispida | amsinckia intermedia | amsinckia lycopsoides | brassica campestris | brassica rapa ssp. sylvestris | brassica rapa var. sylvestris | buglossiodes arvense | burr grass | burrgrass | common lucerne | corn sowthistle | cornbine (uk) | echium lycopsis | echium spp. | european bindweed | fallopia aviculare | false star thistle | field bindweed | field morni

Australia - English - Department of Health (Therapeutic Goods Administration)

avallon pharmaceuticals pty ltd - rosuvastatin calcium, quantity: 41.583 mg - tablet, film coated - excipient ingredients: macrogol 6000; mannitol; purified talc; colloidal anhydrous silica; sodium stearylfumarate; microcrystalline cellulose; silicon dioxide; lactose; hypromellose; maize starch - noumed rosuvastatin is indicated as an adjunct to diet when the response to diet and exercise is inadequate. prevention of cardiovascular events: noumed rosuvastatin is indicated for prevention of major cardiovascular events in men greater than or equal to 50 years old and women greater than or equal to 60 years old with no clinically evident cardiovascular disease but with at least two conventional risk factors for cardiovascular disease (hypertension, low hdl-c, smoking, or a family history of premature coronary heart disease). noumed rosuvastatin is indicated to: - reduce the risk of nonfatal myocardial infarction - reduce the risk of nonfatal stroke - reduce the risk of coronary artery revascularisation procedures.,in patients with hypercholesterolaemia: noumed rosuvastatin is indicated for the treatment of hypercholesterolaemia (excluding familial hypercholesterolaemia). prior to initiating therapy with noumed rosuvastatin, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, alcoholism) should be identified and treated.

Australia - English - Department of Health (Therapeutic Goods Administration)

avallon pharmaceuticals pty ltd - rosuvastatin calcium, quantity: 20.791 mg - tablet, film coated - excipient ingredients: macrogol 6000; hypromellose; silicon dioxide; microcrystalline cellulose; sodium stearylfumarate; lactose; colloidal anhydrous silica; purified talc; maize starch; mannitol - noumed rosuvastatin is indicated as an adjunct to diet when the response to diet and exercise is inadequate. prevention of cardiovascular events: noumed rosuvastatin is indicated for prevention of major cardiovascular events in men greater than or equal to 50 years old and women greater than or equal to 60 years old with no clinically evident cardiovascular disease but with at least two conventional risk factors for cardiovascular disease (hypertension, low hdl-c, smoking, or a family history of premature coronary heart disease). noumed rosuvastatin is indicated to: reduce the risk of nonfatal myocardial infarction; reduce the risk of nonfatal stroke; reduce the risk of coronary artery revascularisation procedures. in patients with hypercholesterolaemia noumed rosuvastatin is indicated for the treatment of hypercholesterolaemia (excluding familial hypercholesterolaemia). prior to initiating therapy with noumed rosuvastatin, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, alcoholism) should be identified and treated.

Australia - English - Department of Health (Therapeutic Goods Administration)

avallon pharmaceuticals pty ltd - rosuvastatin calcium, quantity: 10.396 mg - tablet, film coated - excipient ingredients: lactose; colloidal anhydrous silica; maize starch; hypromellose; sodium stearylfumarate; microcrystalline cellulose; silicon dioxide; purified talc; mannitol; macrogol 6000 - noumed rosuvastatin is indicated as an adjunct to diet when the response to diet and exercise is inadequate. prevention of cardiovascular events: noumed rosuvastatin is indicated for prevention of major cardiovascular events in men greater than or equal to 50 years old and women greater than or equal to 60 years old with no clinically evident cardiovascular disease but with at least two conventional risk factors for cardiovascular disease (hypertension, low hdl-c, smoking, or a family history of premature coronary heart disease). noumed rosuvastatin is indicated to: reduce the risk of nonfatal myocardial infarction; reduce the risk of nonfatal stroke; reduce the risk of coronary artery revascularisation procedures. in patients with hypercholesterolaemia noumed rosuvastatin is indicated for the treatment of hypercholesterolaemia (excluding familial hypercholesterolaemia). prior to initiating therapy with noumed rosuvastatin, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, alcoholism) should be identified and treated.

Australia - English - Department of Health (Therapeutic Goods Administration)

avallon pharmaceuticals pty ltd - rosuvastatin calcium, quantity: 5.198 mg - tablet, film coated - excipient ingredients: hypromellose; maize starch; sodium stearylfumarate; colloidal anhydrous silica; silicon dioxide; mannitol; lactose; microcrystalline cellulose; purified talc; macrogol 6000 - noumed rosuvastatin is indicated as an adjunct to diet when the response to diet and exercise is inadequate. prevention of cardiovascular events: noumed rosuvastatin is indicated for prevention of major cardiovascular events in men greater than or equal to 50 years old and women greater than or equal to 60 years old with no clinically evident cardiovascular disease but with at least two conventional risk factors for cardiovascular disease (hypertension, low hdl-c, smoking, or a family history of premature coronary heart disease). noumed rosuvastatin is indicated to: reduce the risk of nonfatal myocardial infarction; reduce the risk of nonfatal stroke; reduce the risk of coronary artery revascularisation procedures. in patients with hypercholesterolaemia noumed rosuvastatin is indicated for the treatment of hypercholesterolaemia (excluding familial hypercholesterolaemia). prior to initiating therapy with noumed rosuvastatin, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, alcoholism) should be identified and treated.

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - rosuvastatin calcium, quantity: 5.21 mg - tablet, film coated - excipient ingredients: crospovidone; lactose; magnesium stearate; microcrystalline cellulose; light magnesium oxide; hypromellose; triacetin; titanium dioxide; lactose monohydrate; iron oxide yellow - pharmacor rosuvastatin should be used as an adjunct to diet when the response to diet and exercise is inadequate. ,prevention of cardiovascular events pharmacor rosuvastatin is indicated for prevention of major cardiovascular events in men ?50 years old and women ?60 years old with no clinically evident cardiovascular disease but with at least two conventional risk factors for cardiovascular disease (hypertension, low hdl-c, smoking, or a family history of premature coronary heart disease). pharmacor rosuvastatin is indicated to:,? reduce the risk of nonfatal myocardial infarction ? reduce the risk of nonfatal stroke ? reduce the risk of coronary artery revascularisation procedures.,in patients with hypercholesterolaemia pharmacor rosuvastatin is indicated for the treatment of hypercholesterolaemia (including familial hypercholesterolaemia). ,prior to initiating therapy with pharmacor rosuvastatin, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, alcoholism) should be identified and treated.